Syndromic testing

The future of infectious disease diagnostics

Explore our core diagnostic menu and see what's coming next

Get the right diagnosis the first time

Patients with infectious illnesses often have signs and symptoms that are indicative of a disease, but that aren't specific enough to clinically distinguish what makes them ill. These patients are frequently given broad treatment, heavy monitoring and possibly unnecessary interventions. This puts a burden on healthcare systems, clinical labs and clinicians, and means patients aren't getting the best care possible.

We’re committed to helping healthcare workers like you navigate the challenges of diagnosing infectious diseases. That’s why we’ve developed an easy-to-use, automated diagnostic testing system that can help eliminate the guesswork and make your job easier. Our tests use multiplex PCR technology – also known as syndromic testing – that can quickly survey many different pathogens in a single patient sample. With syndromic testing, you get the answers you need, when you need them. And your patients get better care, faster.

Latest insights
–
webinars, stories and more

New to rapid diagnostics with syndromic testing?

Find the information you need and learn how to incorporate syndromic testing into your diagnostic strategy.

Learn more

Your lab in the palm of your hand

What if you could monitor your diagnostic testing status anytime, anywhere? And get around-the-clock proactive technical support? It’s possible with QIAstat-Dx connectivity, powered by QIAsphere.*

Discover QIAsphere

Get fast answers for central nervous system infections

Rapid diagnosis of central nervous system infections is crucial for successful patient outcomes. That's why we've introduced a new syndromic panel that can differentiate 15 pathogens in around 1 hour.

Explore the panel

A professional female laboratory technician in a white coat and blue gloves is operating a modern blue medical device with a touchscreen interface

More tools for infectious diseases

We offer a broad portfolio of diagnostic assays for pathogen detection, viral load measurement and immune monitoring.

Explore portfolio

Voices from the field
–
how medical professionals are using syndromic diagnostics

“It changed our perception, our prescription habits, and it will change the way we work in the future. In the end, we gain money for both the community and the patients. That is really a big step forward.”

Celestin Alexis Agbessi, M.D., Bichat-Claude Bernard Hospital, Paris

“It’s hugely beneficial to be able to test for that wide range of pathogens. Ruling out COVID is helpful, but so is the chance to correctly identify other illnesses so physicians can treat the patients and their symptoms appropriately.”

Michelle Volk, CEO and president of Great Lakes Labs, Indiana, USA

“Our value to our patients and to our provider community has increased by bringing the QIAstat-Dx in-house.”

Joshua Arant, Founder and Chief Operations Officer, Mako Medical

Featured
–
resources for infectious disease diagnostics

Have a question about multiplex panel testing?

Get in touch with us today.

Contact us

References

Yalamanchili H, et al. (2018) Gastroenterol Hepatol, 14(11):646-652
Binnicker M. Multiplex. (2015) J. Clin Microbiology, 53(12):3723-3728
Macfarlane-Smith L, et al. (2018) Gastrointestinal Infections, 34(1):19-2
Echavarria M, et al. (2018) J Clin Virol, 108:90–95
Beal S G, et al. (2018) J Clin Microbiol, 18;56(1)
Bouzid D, et al. (2020) J Hospital Infection, 337-338
Iroh Tam PY, et al. (2017) Children (Basel), 4(1)
Zhu et al. (2018) Clin Pediatr, 58(2): 185-190
Martinez RM, et al. (2016) Clinical Virology Symposium, Poster #C-368

*Some features require a QIAstat-Dx Connectivity plan. Flexible plans are available to meet your lab’s needs.

The QIAstat-Dx Viral Vesicular Panel is for research use only. The QIAstat-Dx Viral Vesicular Panel is run on the QIAstat-Dx Analyzer.

The QIAstat-Dx Analyzer 1.0, QIAstat-Dx Rise, QIAstat-Dx Respiratory SARS-CoV-2 Panel and QIAstat-Dx Gastrointestinal Panel 2 are intended for in vitro diagnostic use.

The QIAstat-Dx ME Panel is indicated as an aid in the diagnosis of specific agents that cause meningitis and/or encephalitis, and results must be used in conjunction with other clinical, epidemiological, and laboratory data. Results from the QIAstat-Dx ME Panel are not intended to be used as the sole basis for diagnosis, treatment, or other patient management decisions. Positive results do not rule out co-infection with organisms not included in the QIAstat-Dx ME Panel. The agent or agents detected may not be the definite cause of the disease. Negative results do not preclude central nervous system (CNS) infection.

The QIAstat-Dx ME Panel is intended for in vitro diagnostic use by laboratory professionals only.

Product availability may differ from country to country based on regulations and approvals. Contact your country representative for further details.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user manual. QIAGEN instructions for use and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services (or your local distributor).